London Based Drug Maker, with 65% Potential Upside. We believe that the market drove down this company to an irrational level, due to its exposure in MENA. A few catalysts are discussed, which can bring this undervalued company back to a more rational valuation. Business description and background: Hikma Pharmaceuticals PLC engages in the development,…
